FOURIER
2017
Further Cardiovascular Outcomes Research with PCSK9 Inhibition
In 27,564 patients with ASCVD on statins, evolocumab reduced CV death, MI, stroke, hosp UA or revasc compared with placebo.
Result
Efficacy: Composite CV eventsHR 0.85 (95% CI 0.79-0.92) · P < 0.001
Below 1 favours evolocumab, above 1 favours placebo.
- Absolute difference
- 1.5 points
- NNT
- 67
Absolute difference and NNT are derived from the event rates.
Also reported: Median LDL 30 mg/dL.
- Subtopic
- PCSK9i
- Design
- Double-blind RCT, median 2.2 yr
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 CCSESC 2023 ACSESC/EAS LipidsESC 2021 PreventionESC 2024 PAADACC/AHA 2025 ACSACC/AHA 2023 CCDACC/AHA 2026 DyslipidaemiaACC/AHA 2024 PAD
- Source
- Sabatine MS, et al. N Engl J Med. 2017;376(18):1713-1722.doi 10.1056/NEJMoa1615664
Discussion & critique
Short follow-up may underestimate effect: extended follow-up suggests larger benefit over time. Cost-effectiveness limits broad uptake; reserved for highest-risk patients.